DOE-Aided Development, Enhancement, and Description of Salicylic acid and Curcumin-Loaded Nanostructure lipid Carrier Gel and its Stability for the Effective Treatment of Atopic Dermatitis
Main Article Content
Abstract
This study aimed to ascertain the potential therapeutic benefits of novel carriers (NLC) loaded with salicylic acid and curcumin for the treatment of atopic dermatitis (AD).
Approach:
A 3-level factorial design (Box-Behenken) version 12 was used to produce and optimise the salicylic acid and curcumin-loaded nanostructure lipid carrier gel. The generated 17 formulations were assessed using FTIR, DSC, HR-TEM, pH, particle size, zeta potential, PDI, percentage yield, % entrapment efficacy, and in vitro drug release. Following that, a gel was created using the optimised batch of Cur-NLCs loaded into Carbopol 934 and salicylic acid. It was then assessed for drug content, pH, washability, spreadability, FTIR, DSC, particle size, zeta potential, PDI, HR-TEM, in vitro drug release and kinetic studies, rheological tests, and organoleptic characteristics.
Outcome:
Particle size, PDI, and Zeta Potential values for the optimised batch of NLCs were 180.60 ± 2.13 nm, 0.25 ± 0.03, and -32.7 ± 0.004 nm, respectively. CUR-NLC-SA-gel adhered to the Korsmeyer Peppas kinetic model and demonstrated continuous drug release for up to 12 hours.
In summary:
In order to efficiently target the skin for the topical delivery of the innovative dosage form to treat atopic dermatitis symptoms and prevent inflammatory consequences, the CUR-NLC-SA-gel demonstrated sustained release and may therefore be used for ex vivo and in vivo research.